National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19 (COVID19PUGG2)

June 12, 2020 updated by: University Hospital, Angers
Cross-sectional study based on a French national survey aimed to described and identify the most frequent symptoms of COVID-19 older patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This cross-sectional survey was initiated and conducted by the French Society of Geriatrics and Gerontology. A standardized questionnaire was emailed to 1600 geriatrician members of the French Society of Geriatrics and Gerontology throughout France between March 22, 2020 and April 5, 2020. Geriatricians were asked to complete the survey for their last 10 patients infected by the SARS-CoV-2. The study was declared to the Commission Nationale de l'Informatique et des Libertés (CNIL) under the number ar20-0031v1.

For each patient, demographic characteristics (age, gender, residence place, care place, autonomy according to the Groupe Iso Ressource (GIR)), medical history (presence of major neurocognitive disorder, hypertension, diabetes, asthma or chronic obstructive pulmonary disease (COPD), heart pathology, severe renal failure with a clearance of creatinine under 30ml/min, solid or liquid cancer) were collected. The symptoms within de 72 hours of the actual disease were also collected for each patient including geriatric syndromes (fall, hypoactive or hyperactive delirium, altered general status, altered conscience), general symptoms (temperature, blood pressure), respiratory symptoms (cough, polypnea), ear nose and throat (ENT) symptoms (rhinorrhea, odynophagia, otalgia, conjunctivitis, ageusia or dysgeusia, anosmia), digestive symptoms (diarrhea, nausea or vomiting), and blood formula modification (leucopenia (with count if available), lymphopenia (with count if available), thrombopenia (with count if available).

Procedure Data were collected by the physician who was in charge of the patient between March 22, 2020 and April 5, 2020.

Given the main objective of the study was only descriptive, no calculation was required concerning the number of subjects to include in the study.

Study Type

Observational

Enrollment (Actual)

353

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Angers, France, 49933 cedex 9
        • Angers University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

all older French patients infected by SARS-CoV-2

Description

Inclusion Criteria:

  • confirmed COVID-19 defined by a positive RT-PCR to SARS-CoV-2

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
symptoms of COVID-19 in older patients
Time Frame: at baseline
description and identification of symptoms presented by older patients with confirmed COVID-19
at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Angers

Investigators

  • Principal Investigator: Cédric Annweiler, M.D., Ph.D., University Hospital, Angers

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 22, 2020

Primary Completion (ACTUAL)

April 5, 2020

Study Completion (ACTUAL)

April 5, 2020

Study Registration Dates

First Submitted

April 9, 2020

First Submitted That Met QC Criteria

April 9, 2020

First Posted (ACTUAL)

April 13, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 16, 2020

Last Update Submitted That Met QC Criteria

June 12, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ar20-0031v1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on observation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe